Related Experiment Video

Updated: Mar 18, 2026

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Lorlatinib Is Active in Drug-Resistant NSCLC

    Cancer Discovery
    |July 13, 2016
    PubMed

    Insights

    The investigational ALK inhibitor lorlatinib shows activity in non-small cell lung cancer, including brain metastases. It is effective in patients with ALK resistance mutations who previously received other tyrosine kinase inhibitors.

    Area of Science:

    • Oncology
    • Pharmacology
    • Genetics

    Background:

    • Non-small cell lung cancer (NSCLC) is a leading cause of cancer death.
    • Anaplastic lymphoma kinase (ALK) and ROS1 gene rearrangements are key drivers in a subset of NSCLC.
    • Resistance to existing tyrosine kinase inhibitors (TKIs) remains a significant clinical challenge.

    Framework:

    • Phase I clinical study evaluating the safety and efficacy of lorlatinib.
    • Lorlatinib is an investigational third-generation ALK and ROS1 inhibitor.
    • Focus on patients with advanced NSCLC, including those with brain metastases and known resistance mutations.

    Implementation:

    • Lorlatinib demonstrated objective responses in patients with ALK- or ROS1-positive NSCLC.
    • Activity was observed in patients with documented ALK resistance mutations.
    • Efficacy was noted in patients who had relapsed after prior TKI treatments.

    Implications:

    • Lorlatinib represents a potential new therapeutic option for TKI-resistant NSCLC.
    • Its activity in brain metastases suggests efficacy in a difficult-to-treat population.
    • Further investigation in phase II/III trials is warranted to confirm these findings.

    More Related Videos

    Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

    Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

    Published on: October 17, 2025

    613
    Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

    Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

    Published on: December 11, 2017

    7.7K

    Related Concept Videos

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

    Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

    Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
    63
    Treatment Resistant Cancers02:56

    Treatment Resistant Cancers

    Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
    3.9K
    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    9.1K
    lncRNA - Long Non-coding RNAs02:39

    lncRNA - Long Non-coding RNAs

    In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
    10.1K
    Treatment Resistent Cancers02:56

    Treatment Resistent Cancers

    1.5K